Autopsy report · NCT02973269

DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

“New trial with same indication initiated”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 months before it stopped.
• 7 participants enrolled.
• Results were posted on the registry 6 years 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Revance Therapeutics, Inc.

Sponsor type

Industry

Conditions

Plantar Fasciitis

Interventions

daxibotulinumtoxin type A; Placebo

Participants

7

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.